Suppr超能文献

PD-L1 siRNA 连接聚乙烯亚胺弹性酶构成的纳米囊泡诱导肿瘤免疫原性和 PD-L1 沉默,用于协同抗肿瘤免疫治疗。

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy.

机构信息

The Center for Clinical Molecular Medical Detection, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Biobank, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

出版信息

J Nanobiotechnology. 2024 Jul 27;22(1):442. doi: 10.1186/s12951-024-02700-4.

Abstract

BACKGROUND

PD-1/PD-L1 blockade has become a powerful method to treat malignant tumors. However, a large proportion of patients still do not benefit from this treatment, due to low tumor immunogenicity and low tumor penetration of the agents. Recently, neutrophil elastase has been shown to induce robust tumor immunogenicity, while the insufficient enzyme activity at the tumor site restricted its anti-tumor application. Here, we designed polyethyleneimine-modified neutrophil elastase (PEI-elastase) loaded with PD-L1small interfering RNA (PD-L1 siRNA) for improving enzymatic activity and delivering siRNA to tumor, which was expected to solve the above-mentioned problems.

RESULTS

We first demonstrated that PEI-elastase possessed high enzymatic activity, which was also identified as an excellent gene-delivery material. Then, we synthesized anti-tumor lipopolymer (P-E/S Lip) by encapsulating PEI-elastase and PD-L1siRNA with pH-responsive anionic liposomes. The P-E/S Lip could be rapidly cleaved in tumor acidic environment, leading to exposure of the PEI-elastase/PD-L1 siRNA. Consequently, PEI-elastase induced powerful tumor immunogenicity upon direct tumor killing with minimal toxicity to normal cells. In parallel, PEI-elastase delivered PD-L1siRNA into the tumor and reduced PD-L1 expression. Orthotopic tumor administration of P-E/S Lip not only attenuated primary tumor growth, but also produced systemic anti-tumor immune response to inhibit growth of distant tumors and metastasis. Moreover, intravenous administration of P-E/S Lip into mice bearing subcutaneous tumors leaded to an effective inhibition of established B16-F10 tumor and 4T1 tumor, with histological analyses indicating an absence of detectable toxicity.

CONCLUSIONS

In our study, a protease-based nanoplatform was used to cooperatively provoke robust tumor immunogenicity and down-regulate PD-L1 expression, which exhibited great potential as a combination therapy for precisely treating solid tumors.

摘要

背景

PD-1/PD-L1 阻断已成为治疗恶性肿瘤的一种强大方法。然而,由于肿瘤免疫原性低和药物对肿瘤的穿透性低,很大一部分患者仍未从中受益。最近,中性粒细胞弹性蛋白酶已被证明可诱导强烈的肿瘤免疫原性,而肿瘤部位酶活性不足限制了其抗肿瘤应用。在这里,我们设计了负载 PD-L1 小干扰 RNA(PD-L1 siRNA)的聚乙烯亚胺修饰的中性粒细胞弹性蛋白酶(PEI-弹性蛋白酶),以提高酶活性并将 siRNA递送至肿瘤,这有望解决上述问题。

结果

我们首先证明了 PEI-弹性蛋白酶具有高酶活性,也被鉴定为一种优良的基因递送材料。然后,我们通过用 pH 响应性阴离子脂质体包封 PEI-弹性蛋白酶和 PD-L1siRNA 合成了抗肿瘤的脂聚合物(P-E/S Lip)。P-E/S Lip 可以在肿瘤酸性环境中迅速被切割,导致 PEI-弹性蛋白酶/PD-L1 siRNA 暴露。因此,PEI-弹性蛋白酶通过直接杀伤肿瘤诱导强大的肿瘤免疫原性,同时对正常细胞的毒性最小。平行地,PEI-弹性蛋白酶将 PD-L1siRNA 递送至肿瘤并降低 PD-L1 表达。P-E/S Lip 的原位肿瘤给药不仅抑制了原发性肿瘤的生长,而且产生了全身性抗肿瘤免疫反应,以抑制远处肿瘤的生长和转移。此外,静脉给予 P-E/S Lip 进入携带皮下肿瘤的小鼠导致对已建立的 B16-F10 肿瘤和 4T1 肿瘤的有效抑制,组织学分析表明没有可检测到的毒性。

结论

在我们的研究中,使用基于蛋白酶的纳米平台协同引发强烈的肿瘤免疫原性并下调 PD-L1 表达,这为精确治疗实体瘤的联合治疗提供了巨大潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c0c/11282766/ddcd8be040c5/12951_2024_2700_Sch1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验